Current and historical daily PE Ratio for Medivir AB (
) from 2013 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Medivir AB stock (MVRBY) PE ratio as of Apr 24 2024 is 0.
More Details
Medivir AB (MVRBY) PE Ratio (TTM) Chart
Medivir AB (MVRBY) PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Total 0
- 1
| Medivir AB PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
Medivir AB (MVRBY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Medivir AB
NAICS : 325412
ISIN : US58502Y1064
Share Class Description:
MVRBY: ADRCompare
Compare
Traded in other countries / regions
MVIR.SwedenMVR0.Germany0GP7.UKMVRBF.USA IPO Date
2013-04-11Description
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers